Global HCQ/CQ studies

May 19, 2021 @CovidAnalysis

Database of all HCQ COVID-19 studies. 294 studies, 219 peer reviewed, 245 comparing treatment and control groups. Submit updates/corrections below. HCQ is not effective when used very late with high dosages over a long period (RECOVERY/SOLIDARITY), effectiveness improves with earlier usage and improved dosing. Early treatment consistently shows positive effects. Negative evaluations typically ignore treatment time, often focusing on a subset of late stage studies. *In Vitro* evidence made some believe that therapeutic levels would not be attained, however that was incorrect, e.g. see *[Ruiz]*.

5/17	Early, <i>Covid Analysis</i> meta-analysis v1 HCQ for COVID-19: real-time meta analysis o • 100% of the 29 early treatment studies report a positive effect (13 statistically significant in isolat
5/17	PrEP Syed et al., me symp. case, ↑59 Pre-Exposure Prophylaxis with Various Dose Small PrEP RCT of low risk patients, showing no significant differences. Authors report that there
5/16	PrEP Rojas-Serrano symp. case, ↓82 Hydroxychloroquine For Prophylaxis Of COVI Early terminated HCQ PrEP RCT with 62 HCQ and 65 placebo patients, showing 82% lower cases
5/10	Late Sammartino et death, ↑240.0%, Predictors for inpatient mortality during the Retrospective 1,108 hospitalized patients in New York showing significantly higher mortality with
5/1	Late De Rosa et al., death, ↓35.0%, p Risk Factors for Mortality in COVID-19 Hospi Retrospective 1,538 hospitalized patients in Italy, showing only HCQ associated with reduced mort
4/30	LateBosaeed et al.,death, ↓3.7%, p=Favipiravir and Hydroxychloroquine CombinaRCT 254 very late stage (93% on oxygen, 17% in ICU at baseline) hospitalized patients in Saudi Ara
4/29	Late Aghajani et al., death, ↓19.5%, p Decreased In-Hospital Mortality Associated Retrospective 991 hospitalized patients in Iran focusing on aspirin use but also showing results fo
4/28	Late <i>Kokturk et al.,</i> death, ↑3.8%, p= The predictors of COVID-19 mortality in a na Retrospective 1,500 hospitalized late stage (median SaO2 87.7) patients in Turkey, showing no sig
4/27	Late <i>Réa-Neto et al</i> death, ↑57.0%, p An open-label randomized controlled trial ev Early terminated very late stage (99% on oxygen, 81% in ICU, 18% on mechanical ventilation at bas

4/26	LateMohandas et adeath, ↑81.0%, pClinical review of COVID-19 patients presentiRetrospective 3,345 hospitalized patients in India, 11.5% treated with HCQ, showing unadjusted hi
4/23	LateToya et al., SSRN (Preprint)A Cross-Country Analysis of the DeterminantCountry based analysis finding lower mortality with the use of HCQ.
4/22	Late Reis et al., JA death , ↓66.0%, p Effect of Early Treatment With Hydroxychlor Early terminated RCT in Brazil showing lower mortality and hospitalization with HCQ, but not reac
4/15	PrEP Alzahrani et al death, 158.8%, p Clinical characteristics and outcome of COVI Retrospective 47 rheumatic disease patients not finding significant differences with HCQ.
4/15	PrEP Alegiani et al., death, ↑8.0%, p= Risk of COVID-19 hospitalization and mortali Retrospective database analysis case control study of rheumatic patients. When compared with o
4/14	PEP Seet et al., Inte severe case, 135 Positive impact of oral hydroxychloroquine a Prophylaxis RCT in Singapore with 3,037 low risk patients, showing lower serious cases, lower sy
4/6	Early <i>Mokhtari et al.,</i> death, 169.7%, p< Clinical outcomes of patients with mild COVI Retrospective 28,759 adult outpatients with mild COVID-19 in Iran, 7,295 treated with HCQ, showin
4/5	SafetyEdington et al.,safety analysisSafety of treatment with chloroquine and hySafety analysis of CQ and HCQ covering 46 RCTs with 23,132 patients, showing no mortality attrib
3/31	Late Alghamdi et al death, ↑6.9%, p= Clinical Efficacy of Hydroxychloroquine in Pa Retrospective 775 hospitalized patients in Saudi Arabia showing no significant difference. There w
3/26	SafetyFaruqui et al., Isafety analysisSafety of hydroxychloroquine in healthcareRetrospective 1303 health care workers finding that HCQ prophylaxis was well tolerated. 20% repo
3/24	PrEP Dev et al., Tran cases, 126.0%, p Risk factors and frequency of COVID-19 am Retrospective case control study of 3,100 healthcare workers in India showing lower cases with H
3/23	LateBarry et al., Intdeath, 198.9%, pClinical Characteristics and Outcomes of Ho605 hospitalized patients in Saudi Arabia showing no mortality with HCQ (only 6 patients received
3/17	LateStewart et al.,death, ↑18.0%, pCOVID-19 Evidence Accelerator: A parallel anCollection of seven retrospective database analyses in the USA, showing higher mortality with trea
3/17	In Vit Dang et al., bio in vitro Structural basis of anti-SARS-CoV-2 activity Microscopy/spectroscopy study showing that HCQ binds to both N-terminal domain and C-termin

3/12	Early Roy et al., med recov. time, 12.4 Outcome of Different Therapeutic Interventio Retrospective database analysis of 56 mild COVID-19 patients, all treated with vitamin C, vitamin D
3/9	PrEP Vivanco-Hidal hosp., ^{46.0} %, p= Incidence of COVID-19 in patients exposed t Retrospective database analysis of chronic HCQ users and matched control patients, failing to ma
3/8	LateMartin-Vicentedeath, ↓59.3%, pAbsent or insufficient anti-SARS-CoV-2 S antiRetrospective 92 ICU patients with almost all treated with HCQ and only one non-HCQ treated pati
3/4	Late Salvador et al., death , ↓32.9% , p Clinical Features and Prognostic Factors of Prospective study of 245 hospitalized patients, 121 treated with HCQ, showing lower (non-statistic
3/2	PrEP <i>Pham et al., Rh</i> death, 19.7%, p Failure of chronic hydroxychloroquine in prev Tiny retrospective database analysis of hospitalized COVID-19 patients with rheumatologic diseas
2/28	Early Thakar et al., Indian J. Med. Res., doi:1 Chloroquine nasal drops in asymptomatic & Small RCT for CQ nasal drops suggesting efficacy in preventing infection, while no significant diffe
2/28	PrEP Bhandari et al., International Journal o A Preventive Study on Hydroxychloroquine P Retrospective 4,239 healthcare workers using HCQ prophylaxis showing no mortality, 8 mild symp
2/26	Early Amaravadi et no recov., 160.0% Hydroxychloroquine for SARS-CoV-2 positive Tiny early-terminated 34 patient RCT for outpatient treatment showing faster recovery with treatm
2/26	LateTanriverdi et al., Turkish Journal of MeHydroxychloroquine plus azithromycin and eRetrospective 83 hospitalized patients in Turkey confirming that earlier treatment is better, and sh
2/26	Early <i>Giraud-Gatineau et al., Research Squa</i> The Need for Early Management in Patients Review of early treatment of COVID-19 at IHU Méditerranée Infection in France, including HCQ+AZ
2/23	LateGonzalez et aldeath, $\downarrow 62.6\%$, pEfficacy and safety of Ivermectin and HydroxRCT late stage severe condition (93% SOFA \geq 2, 96% APACHE \geq 8) high comorbidity hospitalized p
2/20	PrEP Bae et al., Viru cases, 130.3%, p Recent Hydroxychloroquine Use Is Not Signi Retrospective database analysis of prior HCQ usage in South Korea, showing non-statistically sign
2/19	Late Lamback et al., death, ↓8.9%, p= Hydroxychloroquine with azithromycin in pat Retrospective 193 hospitalized patients in Brazil not finding a significant difference with HCQ. The
2/18	Late Awad et al., A death, ↑19.1%, p Impact of hydroxychloroquine on disease pr This paper has inconsistent values - the number of treatment and control patients differs in the te

2/11	Late <i>Lora-Tamayo</i> e death , ↓50.5% , p< Early Lopinavir/ritonavir does not reduce mo Lopinavir/ritonavir retrospective study also showing univariate results for HCQ, with significantly I
2/10	Early, Desai et al., J. Clinical Medicine, doi:10 The Use of Antiviral Agents against SARS-Co Retrospective 143 COVID-19 hospitalized patients >65yo, showing adjusted OR for antiviral treatm
2/9	MetaLounnas e al.,meta-analysisRevisiting a Meta-analysis Shows that HydroAnalysis of the Fiolet meta analysis and correction of bias evaluation, showing HCQ RR 0.45 [0.31
2/9	Late <i>Purwati et al.,</i> viral+, 166.3%, p< A Randomized, Double-Blind, Multicenter Cli RCT 754 patients comparing HCQ+AZ along with other treatment groups using lopinavir/ritonavir
2/5	PrEP <i>Fitzgerald et al</i> cases, 18.5%, p= Risk Factors for Infection and Health Impact Retrospective 4666 people with autoimmune or inflammatory conditions, showing HCQ adjusted r
2/5	LateHernandez-Cardeath, ↓12.0%, pHydroxychloroquine for the treatment of sevVery late stage RCT with 214 patients, mean SpO2 65%, 162 on mechanical ventilation, showing n
2/5	LateOuedraogo etdeath, \downarrow 33.0%, pFactors associated with the occurrence of aRetrospective 456 patients in Burkina Faso showing lower risk of ARDS (p =0.001) and mortality (p
2/1	ReviAlexander et alreviewEarly Multidrug Outpatient Treatment of SARReview of studies on treatment of COVID-19 for nursing home residents, concluding that there is a
2/1	LateUbaldo et al., Cdeath, \downarrow 18.4%, pCOVID-19: A Single-Center ICU Experience ofRetrospective ICU patients in the Philippines showing unadjusted HCQ RR 0.82, p = 0.64.
1/31	PrEPNaderi et al., Immunopathologia PersaProphylactic effects of hydroxychloroquine oProspective observational study of 215 RA patients treated with HCQ showing 9 cases, 1 hospitali
1/31	Late <i>Roig et al., Revi</i> death, ↓15.6%, p Clinical and pharmacological data in COVID Retrospective 79 hospitalized nonagenarian patients showing unadjusted HCQ mortality RR 0.84,
1/27	PrEP Trefond et al., death, ↑16.6%, p Impact of hydroxychloroquine used as DMA Retrospective 71 chronic HCQ patients compared with 191 matched controls, analyzing only thos
1/26	SafetyEftekhar et al.,safety analysisHydroxychloroquine and azithromycin: As aRetrospective 172 hospitalized patients, 83% treated and HCQ+AZ and 17% with HCQ, not finding
1/25	Early Dabbous et al., Archives of Virology, d Efficacy of favipiravir in COVID-19 treatment: RCT with 44 favipiravir patients and 48 CQ patients, showing non-statistically significant lower mo

1/25	In Sili Hussein et al., Journal of Molecular St Molecular Docking Identification for the effic Molecular dynamics analysis recommending Zn (CQ) Cl2(H2O) and Zn (HCQ) Cl2(H2O) as potenti
1/24	EarlyZelenko, Z., Preprint (Preprint)Nebulized Hydroxychloroquine for COVID-19Report on the use of nebulized HCQ showing much more rapid improvement compared to tablets,
1/23	PrEPCifuentes et al., Medicina Clínica (EnglIncidence of COVID-19 in patients under chrRetrospective 3,817 chronic HCQ patients showing 4.4% COVID-19 positive rate, 1.3% severe. Ther
1/18	LateLi et al., Sciencno disch., ↓50.0%Evaluation of the efficacy and safety of hydrSmall RCT comparing HCQ and CQ in China with 88 very late stage (17.6 days from onset to hospi
1/12	Late <i>Li et al., Resear</i> viral- time, ↑40.0 Treatment of COVID-19 patients with hydrox Small retrospective database analysis of 37 late stage patients hospitalized in an intensive care ce
1/10	PrEP Rangel et al., J death, ↓25.1%, p Chronic Hydroxychloroquine Therapy and C Retrospective 50 COVID-19 patients that take chronic HCQ, compared to a matched sample of pat
1/8	Late Yegerov et al., death , ↓95.3%, p Epidemiological and Clinical Characteristics, Retrospective 1,072 hospitalized patients in Kazakhstan showing no mortality for HCQ treated pati
1/7	In Sili Baildya et al., Journal of Molecular Str Inhibitory capacity of Chloroquine against S Molecular docking study of 16 drugs showing CQ had the highest binding affinity with ACE2, and
1/6	TheoNoureddine ettheoryQuantum chemical studies on molecular strIn silico analysis of hydroxychloroquine and hydroxychloroquine sulfate predicting that hydroxychl
1/4	SafetyGautret et al., Isafety analysisSafety profile of hydroxychloroquine and azitReport on the safety of HCQ+AZ with 3,737 COVID-19 patients. 138 had contraindications and trea
1/2	Late Sarfaraz et al., death, \uparrow 45.0%, p Determinants of in-hospital mortality in COVI Retrospective 186 hospitalized patients in Pakistan showing unadjusted HCQ mortality RR 1.45, p
1/1	Late Lotfy et al., Tur death, ↑24.8%, p Use of Hydroxychloroquine in Patients with Retrospective 202 patients in Saudi Arabia not showing significant differences with treatment. No
1/1	Late Sands et al., In death, $\uparrow 69.9\%$, p No clinical benefit in mortality associated wit Retrospective database analysis of 1,669 patients in the US showing OR 1.81, $p = 0.01$. Confoundi
12/31	ReviMatada et al.,reviewA comprehensive review on the biological intReview of quinolone and derivatives, natural and drug sources, and biological activity.

12/31	LatePsevdos et al.,death, ↑63.5%, pCorona Virus Disease-19 (COVID-19) in a VetRetrospective 67 hospitalized patients in the USA showing non-statistically significant unadjusted
12/31	Late Texeira et al., death, ↑79.3%, p Characteristics and outcomes of COVID-19 Retrospective 161 hospitalized patients in the USA showing non-statistically significant unadjuste
12/31	LateVernaz et al., Sdeath, ↓15.3%, pEarly experimental COVID-19 therapies: assoRetrospective 840 hospitalized patients in Switzerland showing non-statistically significant lower
12/30	ReviMcCullough etreviewMultifaceted highly targeted sequential multiReview urging early treatment of COVID-19 with sequential multidrug treatment that has been sho
12/30	Early Procter et al., Reviews in Cardiovascul Clinical outcomes after early ambulatory mu Retrospective 922 outpatients, with 320 treated early due to age>50 or comorbidities, showing 2.2
12/29	Late Güner et al., Jo ICU, 177.3%, p=0 Comparing ICU Admission Rates of Mild/Mo Retrospective 824 hospitalized patients in Turkey showing lower ICU admission for HCQ vs. favipir
12/28	PrEP <i>Cordtz et al., R</i> hosp., <i>124.0%, p=</i> Incidence and severeness of COVID-19 hosp Retrospective 58,052 rheumatic disease patients in Denmark showing that RA patients have a hig
12/24	Late Chari et al., Blo death, ↓33.1%, p Clinical features associated with COVID-19 o Retrospective multiple myeloma patients showing lower mortality with HCQ treatment, unadjuste
12/23	Early Su et al., BioSc progression, ↓84 Efficacy of early hydroxychloroquine treatme 85% lower disease progression with early use of HCQ. Retrospective 616 patients in China showin
12/23	LateTaccone et al.,death, ↓24.7%, pThe role of organizational characteristics onRetrospective 1,747 ICU patients in Belgium showing lower mortality with HCQ, multivariate mixed
12/22	LateCangiano et aldeath, ↓73.4%, pMortality in an Italian nursing home during C73% lower mortality with HCQ. Analysis of 98 PCR+ nursing home residents in Italy, mean age 90,
12/19	PrEP Huh et al., Inter progression, ↑25 Association of prescribed medications with t Retrospective database analysis with 17 existing users of HCQ and 5 severe cases, showing no si
12/18	LateMatangila et aldeath, ↓54.9%, pClinical characteristics of COVID-19 patients55% lower death with HCQ+AZ. Retrospective 160 hospitalized patients in the Democratic Republi
12/16	Late Signes-Costa death, 147.0%, p Prevalence and 30-day mortality in hospitaliz

	47% lower mortality with HCQ/CQ. Retrospective 1,271 patients with lung disease in Canada, Chin
12/16	PrEP Gönenli et al., progression, 129 Prophylactic use of Hydroxychloroquine am Small prophylaxis survey showing lower, but not statistically significant, progression to pneumonia
12/14	LateSofian et al., Wiener Medizinische WoSARS-CoV-2, a virus with many faces: a seriReport on a series of 10 patients experiencing prolonged COVID-19 symptoms that were given HC
12/14	Late Orioli et al., Dia death, 12.7%, p Clinical characteristics and short-term progn Small retrospective study of 73 diabetic patients in Belgium, 55 HCQ patients, showing HCQ RR 0
12/14	Late Naseem et al., death , J33.3% , p Predicting mortality in SARS-COV-2 (COVID Retrospective 1,214 hospitalized patients in Pakistan, 77 HCQ patients, showing 33% lower mortal
12/14	Late Tan et al., Viru hosp. time, ↓35.2 A retrospective comparison of drugs against Retrospective 333 patients in China, with only 8 HCQ patients, showing shorter duration of hospita
12/11	Late Bielza et al., Jo death, 121.5%, p Clinical characteristics, frailty and mortality Retrospective 630 elderly patients in Spain showing lower mortality with HCQ treatment, unadjust
12/11	Early Sogut et al., Th safety analysis Safety and efficacy of hydroxychloroquine in Safety study of 152 outpatients concluding that HCQ is safe for COVID-19, was well tolerated, and
12/11	PrEP Jung et al., Cli death, ↓59.3%, p Effect of hydroxychloroquine pre-exposure o Retrospective cohort study of RA and SLE patients not showing a significant difference in PCR+ c
12/10	Late Alqassieh et al hosp. time, 18.2 Clinical characteristics and predictors of the Prospective observational study of 131 COVID-19 patients in Jordan, showing 18% shorter hospita
12/10	NewsItalian CouncilnewsConsiglio di Stato, sì all'uso dell'idrossicloracConsiglio di Stato ruling in Italy re-establishes the right of Italian MDs to prescribe HCQ, which was
12/9	Late Johnston et al hosp., 129.9%, p= Hydroxychloroquine with or Without Azithro Small early terminated late treatment RCT comparing vitamin C + folic acid, HCQ + folic acid, and
12/9	Early Agusti et al., E progression, 168 Efficacy and safety of hydroxychloroquine in Small trial of low dose HCQ for healthcare workers with mild SARS-CoV-2 showing 68% lower prog
12/9	Late Guglielmetti et death, 135.0%, p Severe COVID-19 pneumonia in Piacenza, Ita Retrospective 218 hospitalized patients in Italy showing non-statistically significant 35% lower mo
12/7	

	PEPBarnabas et alhosp., ↑3.7%, p=1Hydroxychloroquine for Post-exposure PropEarly terminated PEP RCT comparing HCQ and vitamin C with 781 low-risk patients (83% househo
12/4	Late <i>Ozturk et al., N</i> death, ↓43.9%, p Mortality analysis of COVID-19 infection in c Retrospective 1210 hospitalized patients in Turkey focused on chronic kidney disease, haemodialy
12/4	Late <i>Modrák et al.,</i> death, ↓59.0%, p Detailed disease progression of 213 patients Retrospective 213 hospitalized patients in Czech Republic showing lower mortality with HCQ. Subj
12/4	Late Peng et al., Ne progression , 10 Early versus late acute kidney injury among Retrospective 4020 hospitalized patients in China showing non-statistically significant lower risk o
12/2	PEPWiseman et alcases, \$42.0%, pEffective post-exposure prophylaxis of Covid6th independent analysis showing efficacy from the Boulware PEP trial. This prospective analysis
12/1	Late Capsoni et al., ventilation, 140.0 CPAP Treatment In COVID-19 Patients: A Ret Small 52 patient retrospective study of patients with acute respiratory failure showing lower rates
11/30	LateAbdulrahmandeath, 16.7%, pThe efficacy and safety of hydroxychloroquinRetrospective medical record analysis of acute care patients in Bahrain not showing a significant
11/29	LateAbd-Elsalam et al., Biological Trace ElDo Zinc Supplements Enhance the Clinical E191 patient RCT in Egypt comparing the addition of zinc to HCQ, not showing a significant differen
11/28	Late Lambermont e death, J32.3%, p Predictors of Mortality and Effect of Drug Th Retrospective 247 mechanically ventilated patients showing lower mortality with HCQ, but not stat
11/28	N/ARuiz et al., Intedosing studyHydroxychloroquine lung pharmacokinetics iHCQ lung pharmacokinetic study confirming that lung concentrations can be much higher than pl
11/28	Late Rodriguez-Gon death, 122.8%, p COVID-19 in hospitalized patients in Spain: a Retrospective 1255 patients in Spain showing lower mortality with HCQ. Subject to confounding b
11/27	Late van Halem et a death, 131.6%, p Risk factors for mortality in hospitalized pati Retrospective 319 hospitalized patients in Belgium showing lower mortality with HCQ, although no
11/24	LateAbbas et al., Int. J. Clin. Pract., doi:10Assessment of COVID-19 Treatment containProspective study of 161 hospitalized patients in Iraq showing HCQ+AZ appears to help recovery
11/23	Late <i>Qin et al., Thro</i> death, ↓34.3%, p Low molecular weight heparin and 28-day m Low molecular weight heparin study also showing results for HCQ treatment, unadjusted HCQ mo

11/21	PrEP Revollo et al., J cases, 123.0%, p Hydroxychloroquine pre-exposure prophylaxi Retrospective PrEP analysis with 69 healthcare workers on PrEP HCQ, and 418 control. Authors re
11/20	Early Omrani et al., E hosp., 12.5%, p= Randomized double-blinded placebo-controll Low risk patient RCT for HCQ+AZ and HCQ vs. control, not showing any significant differences. Au
11/19	LateFalcone et al.,death, ↓65.0%, pRole of low-molecular weight heparin in hosProspective observational study of 315 hospitalized patients in Italy showing 65% lower mortality
11/18	Late Budhiraja et al death , ↓65.4% , p< Clinical Profile of First 1000 COVID-19 Cases Retrospective 976 hospitalized patients with 834 treated with HCQ+AZ showing HCQ mortality rel
11/17	LateBoari et al, Biodeath, ↓54.5%, p<
11/13	Late Sheshah et al., death, ↓80.0%, p< Prevalence of Diabetes, Management and O Retrospective 300 hospitalized patients in Saudi Arabia showing HCQ adjusted odds ratio aOR 0.1
11/12	Early Simova et al., hosp., 193.8%, p= Hydroxychloroquine for prophylaxis and trea 100% reduction in hospitalization and cases with early treatment using HCQ+AZ+zinc. Brief report
11/12	PEPSimova et al.,cases, 192.7%, pHydroxychloroquine for prophylaxis and trea100% reduction in cases with HCQ+zinc post-exposure prophylaxis. Brief report for healthcare wor
11/12	N/A <i>Tchounga</i> et al meta-analysis Composition analysis of falsified chloroquin Analysis of fake CQ tablets finding: - no CQ in six samples, substituted with metronidazole (at sub
11/11	LateÁguila-Gordo edeath, ↓67.0%, pMortality and associated prognostic factors67% lower mortality with HCQ. Retrospective 416 elderly patients in Spain showing adjusted HCQ
11/9	LateKhamis et al., International Journal ofRandomized Controlled Open Label Trial on tSmall 89 patient RCT comparing favipiravir and inhaled interferon with HCQ for moderate to sever
11/9	LateRodriguez et aldeath, ↓59.0%, pSevere infection due to the SARS-CoV-2 coroSmall prospective study of 43 hospitalized patients with 39 taking HCQ, showing unadjusted mort
11/9	Late Self et al., JAM death, ↑6.2%, p= Effect of Hydroxychloroquine on Clinical Stat Early terminated very late stage (65% on supplemental oxygen) RCT with 242 HCQ and 237 contro
11/9	LateBrown et al., Annals of the American THydroxychloroquine vs. Azithromycin for HoSmall early terminated very late stage (86% on oxygen, 44% enrolled in the ICU) RCT comparing H

11/9	Late <i>Núñez-Gil et al</i> death, ↓7.9%, p= Mortality risk assessment in Spain and Italy, Retrospective database study of 1,021 patients in Ecuador, Germany, Italy, and Spain, showing HC
11/6	PrEPMathai et al., Jcases, ↓89.5%, pHydroxychloroquine as pre-exposure prophyl90% reduction in cases with HCQ pre-exposure prophylaxis. Retrospective 604 healthcare workers.
11/6	PrEPDatta et al., Journal of Vaccines & VacNo Role of HCQ in COVID-19 Prophylaxis: ASurvey of Indian doctors not finding a significant effect of HCQ prophylaxis, $p = 0.54$. We do not kn
11/6	PEPDhibar et al., Incases, 141.0%, pPost Exposure Prophylaxis with Hydroxychlo41% reduction in cases with HCQ PEP. Prospective open label trial with 132 HCQ patients and 185
11/5	LateMaldonado etdeath, ↓90.9%, pCOVID-19 incidence and outcomes in a homSmall retrospective 12 dialysis patients, 1/11 deaths with HCQ and 1/1 without HCQ.
11/5	Late Rodriguez-Nav death, ↑6.3%, p= Clinical characteristics and risk factors for m Retrospective 313 patients, mostly critical stage and mostly requiring respiratory support, showin
11/4	Late Salazar et al., death, ↑37.0%, p Significantly Decreased Mortality in a Large Convalescent plasma study also showing mortality based on HCQ treatment, unadjusted hazard r
11/4	Early Cadegiani et al death , 181.2% , p Early COVID-19 Therapy with Azithromycin P Comparison of HCQ, nitazoxanide, and ivermectin showing similar effectiveness for overall clinical
11/3	PrEP Behera et al., P cases, 127.9%, p Role of ivermectin in the prevention of SARS Retrospective matched case-control prophylaxis study for HCQ, ivermectin, and vitamin C with 37
11/2	LateLópez et al., Aprogression, $\downarrow 64$ Telemedicine follow-ups for COVID-19: experRetrospective 72 pediatric patients showing HCQ associated with a shorter duration of fever ($p=0$)
10/31	Early Szente Fonsec hosp., ↓64.0%, p= Risk of Hospitalization for Covid-19 Outpatie 64% lower hospitalization with HCQ. Retrospective 717 patients in Brazil with early treatment, adju
10/30	Late Tehrani et al., I death , \downarrow 13.4% , p Risk factors for mortality in adult COVID-19 Retrospective 255 hospitalized patients, 65 treated with HCQ, showing unadjusted RR 0.87, p=0.6
10/27	PrEP Arleo et al., me death, ↓50.0%, p Clinical Course and Outcomes of coronaviru Retrospective hospitalized rheumatic disease patients showing 50% lower mortality for patients o
10/27	Late Choi et al., Inte viral- time, ↑22.0 Comparison of antiviral effect for mild-to-mo Health insurance database analysis failing to adjust for disease severity and not finding a significa

10/26	Late <i>Frontera</i> et al., death, 137.0%, p Treatment with Zinc is Associated with Redu Retrospective 3,473 hospitalized patients showing lower mortality with HCQ+zinc.
10/26	Early Derwand et al., death , ↓79.4% , p COVID-19 Outpatients – Early Risk-Stratified 79% lower mortality and 82% lower hospitalization with early HCQ+AZ+Z. No cardiac side effects
10/24	PrEP <i>Goenka et al.,</i> IgG+, ↓87.2%, p= Seroprevalence of COVID-19 Amongst Healt Study of SARS-CoV-2-IgG antibodies in 1122 health care workers in India finding 87% lower positiv
10/23	Late <i>Coll et al., Ame</i> death, ↓45.6%, p< Covid-19 in transplant recipients: the spanis Retrospective 652 transplant recipient patients in Spain showing 46% lower mortality for patients t
10/21	LateLano et al., Clideath, ↓33.1%, pRisk factors for severity of COVID-19 in chro33% lower mortality with HCQ+AZ, p=0.28. Retrospective 122 French dialysis patients. 69% lower
10/21	Late Dubee et al., Cl death , ↓ 46.0% , p Hydroxychloroquine in mild-to-moderate CO Small early terminated late stage (60% on oxygen) RCT in France showing 46% lower mortality. m
10/21	Late <i>Ñamendys-Silv</i> death, ↓32.3%, p Outcomes of patients with COVID-19 in the I Retrospective 164 ICU patients in Mexico showing 32% lower mortality with HCQ+AZ and 37% low
10/20	Early, IHU Marseille (meta-analysis Meta-analysis on chloroquine derivatives an Updated meta analysis of 41 studies showing CQ/HCQ OR 0.57, p<0.0001 from clinical studies. Fo
10/20	Late Solh et al., me death, ↑18.0%, p Clinical course and outcome of COVID-19 ac Retrospective database analysis of 7,816 Veterans Affairs hospitalized patients analyzing progres
10/17	Early <i>Mohana et al.,</i> safety analysis Hydroxychloroquine Safety Outcome within Safety study of 2,733 patients in Saudi Arabia showing HCQ in mild to moderate cases in an outpa
10/15	Late <i>Guisado-Vasc</i> death, ↓20.3%, p Clinical characteristics and outcomes amon Retrospective 607 patients reporting results for early outpatient HCQ use with mortality odds ratio
10/15	Late SOLIDARITY Tr death, ↑19.0%, p Repurposed antiviral drugs for COVID-19; int WHO SOLIDARITY open-label trial with 954 very late stage (64% on oxygen/ventilation) HCQ patie
10/12	Late Annie et al., Ph death, 14.3%, p= Hydroxychloroquine in hospitalized COVID-1 Retrospective database analysis with PSM not including COVID-19 severity, finding mortality OR 0
10/11	LateSili et al., medRxiv, doi:10.1101/2020Factors associated with progression to criticAnalysis of hospitalized patients in Turkey showing HCQ was given to 99.2% of patients and the in

10/8	LateAparisi et al.,death, ↓63.0%, pLow-density lipoprotein cholesterol levels arRetrospective 654 hospitalized patients focused on low-density lipoprotein cholesterol levels, also
10/8	Late Soto-Becerra e death, ↓18.1%, p< Real-World Effectiveness of hydroxychloroqu Retrospective database study of 5683 patients, 692 received HCQ/CQ+AZ, 200 received HCQ/CQ,
10/6	LateAder et al., medeath, ↓6.4%, p=Antiviral drugs in hospitalized patients withEarly terminated very late stage (95% on oxygen at baseline) DISCOVERY trial. 4% more patients w
10/5	LateMori et al., Journal of Microbiology, ImTriple therapy with hydroxychloroquine, azithSmall case study of 5 patients in Japan showing improvement with HCQ+AZ+ciclesonide.
10/5	Early,Prodromos etmeta-analysisHydroxychloroquine is effective, and consistMeta analysis of 43 studies: "HCQ was found consistently effective against COVID-19 when used
10/2	Late Nachega et al., death, 127.6%, p Clinical Characteristics and Outcomes of Pat Retrospective 766 hospitalized patients in DRC showing mortality reduced from 29% to 11%, and i
10/1	Late Almazrou et al ventilation, 165.0 Comparing the impact of Hydroxychloroquin Retrospective 161 hospitalized patients in Saudi Arabia showing lower ventilation and ICU admissi
10/1	PrEP, Garcia-Albeniz cases, 122.0%, p Brief communication: A meta-analysis of ran Combination of the four underpowered prophylaxis RCTs to date showing statistically significant r
9/30	PEPPolat et al., Mecases, 157.0%, pHydroxychloroquine Use on Healthcare WorkSmall prophylaxis study of 208 healthcare workers in Turkey, 138 with high risk exposure received
9/30	Late Ayerbe et al., I death, \downarrow 52.2%, p< The association of treatment with hydroxych 2075 hospital patients in Spain showing HCQ reduces mortality 52%, odds ratio OR 0.39, p<0.001,
9/30	PrEP, Ladapo et al., cases/death/hos Randomized Controlled Trials of Early Ambul Meta analysis of prophylactic and early treatment RCTs, 24% reduction in cases, hospitalization or
9/30	PrEP Abella et al., J cases, 15.0%, p= Efficacy and Safety of Hydroxychloroquine v Very small early-terminated underpowered PrEP RCT with 64/61 HCQ/control patients and only 8 i
9/29	LateLammers et aldeath/ICU, ↓32.0Early hydroxychloroquine but not chloroquinObservational study 1,064 hospitalized patients in the Netherlands, 53% reduced risk of transfer to
9/29	Late Dabbous et al., Research Square, doi:1 A Randomized Controlled Study Of Favipiravi

	Small RCT comparing HCQ and favipiravir, with 50 patients in each arm, finding that 55.1% of HCQ
9/28	PEPLuco, J., Trendmeta-analysisHydroxychloroquine as post-exposure prophReanalysis of Boulware et al. PEP trial data showing statistically significant improvements with H
9/24	Early, Gasperetti et a safety analysis Arrhythmic safety of hydroxychloroquine in Safety study of 649 patients finding that HCQ administration is safe for short-term treatment for p
9/24	Late Shoaibi et al., death, 15.4%, p< Comparative Effectiveness of Famotidine in Retrospective database analysis focused on Famotidine but also showing results for HCQ users,
9/23	Late Ulrich et al., Op death, ↑6.0%, p= Treating Covid-19 With Hydroxychloroquine (Small RCT on very late stage use of HCQ, with 48% on oxygen at baseline. 67 HCQ patients, 61 co
9/22	Late Serrano et al., death, 143.0%, p COVID-19 and lung cancer: What do we know? Small retrospective study of 22 lung cancer patients, 14 treated with HCQ+AZ, showing HCQ+AZ
9/21	PrEP <i>Gentry et al., L</i> death, 191.3%, p Long-term hydroxychloroquine use in patient Retrospective patients with rheumatologic conditions showing zero of 10,703 COVID-19 deaths fo
9/21	PrEPRajasingham ecases, $\downarrow 27.0\%$, pHydroxychloroquine as pre-exposure prophylPrEP RCT showing HR 0.73, $p = 0.12$. Trial halted after 47% enrollment, $p < 0.05$ will be reached at
9/21	PrEP <i>Grau-Pujol et a</i> cases, 167.9%, p Pre-exposure prophylaxis with hydroxychloro Small PrEP RCT showing that PrEP with HCQ is safe at the dosage used. No deaths, hospitalizatio
9/21	Early Lofgren et al., safety analysis Safety of Hydroxychloroquine among Outpat Analysis of 2,795 outpatients not showing significant safety concerns with HCQ. No deaths were r
9/18	LateAxfors et al., Nmeta-analysisMortality outcomes with hydroxychloroquineMeta analysis assigning 89% weight to the RECOVERY and SOLIDARITY trials, producing the same
9/16	N/AKaratza et al.,dosing studyOptimization of hydroxychloroquine dosing sAnalysis of HCQ dosing, suggesting that high initial doses followed by low and sparse doses may
9/15	Late Ashinyo et al., hosp. time, ↓33.0 Clinical characteristics, treatment regimen a Retrospective 307 hospital patients in Ghana showing 33% reduction in hospitalization time with
9/14	Late Lauriola et al., death, ↓73.5%, p< Effect of combination therapy of hydroxychl Retrospective 377 patients, 73% reduction in mortality with HCQ+AZ, adjusted hazard ratio HR 0.2
9/13	

	Early Sulaiman et al death, \downarrow 63.7%, p The Effect of Early Hydroxychloroquine-base Observational prospective 5,541 patients, adjusted HCQ mortality odds ratio OR 0.36, p = 0.012. A
9/12	Late Heberto et al., death, \downarrow 53.6%, p Implications of myocardial injury in Mexican Observational prospective 254 hospitalized patients, HCQ+AZ mortality odds ratio OR 0.36, $p = 0.0$
9/9	Late Alamdari et al., death, \downarrow 55.0%, p Mortality Risk Factors among Hospitalized C Retrospective 459 patients in Iran 93% using HCQ, showing HCQ mortality RR 0.45, $p = 0.028$. HC
9/9	Early, <i>Kirenga et al.,</i> recov. time, ↓25 Characteristics and outcomes of admitted p Prospective 56 patients in Uganda, 29 HCQ and 27 control, showing 25.6% faster recovery with HC
9/9	PrEP Rentsch et al., death, ↑3.0%, p= Effect of pre-exposure use of hydroxychloro Observational database study of RA/SLE patients in the UK, 194,637 RA/SLE patients with 30,569
9/9	PrEP Laplana et al., cases, ↑56.0%, p Lack of protective effect of chloroquine deriv Survey of 319 autoimmune disease patients taking CQ/HCQ with 5.3% COVID-19 incidence, comp
9/7	ReviIHU, Expert RereviewNatural history and therapeutic options for CReview of the current state of knowledge regarding the natural history of and therapeutic options f
9/5	Late Synolaki et al., death, 123.6%, p The Activin/Follistatin-axis is severely dereg Retrospective 117 patients, 58 HCQ showing lower mortality for HCQ patients. Version 1 of this pa
9/4	LateFurtado et al., The Lancet, doi:10.1016Azithromycin in addition to standard of careSmall RCT comparing the addition of AZ for very late stage patients on ventilation or oxygen. No si
9/2	In Vit Wang et al., Ph in vitro Chloroquine and hydroxychloroquine as ACE In Vitro study providing novel insights into the molecular mechanism of CQ/HCQ treatment, showi
9/2	Early Heras et al., Eu death, 195.6%, p COVID-19 mortality risk factors in older peop Retrospective 100 elderly nursing home patients, HCQ+AZ mortality 11.4% vs. control 61.9%, RR 0
9/2	PrEP <i>de la Iglesia</i> et hosp., ↑50.0%, p= Hydroxicloroquine for pre-exposure prophyyl Analysis of autoimmune disease patients on HCQ, compared to a control group from the general p
9/1	ReviHecel et al., PhreviewZinc(II)—The Overlooked Éminence Grise ofReview of zinc as an inhibitor of SARS-CoV-2's RNA-dependent RNA polymerase, and zinc ionopho
9/1	Early <i>Elbazidi et al., New Microbes and New</i> Pandemic and social changes, political fate Analysis of US states and countries. Country analysis shows a significant correlation between the

8/30	Late Albani et al., J, death, 18.4%, p Impact of Azithromycin and/or Hydroxychlor Retrospective 1376 hospitalized patients in Italy, 211 treated with HCQ and 166 with HCQ+AZ.
8/29	Late Castillo et al., Journal of Steroid Bioch Effect of calcifediol treatment and best avail RCT on calcifediol (25-hydroxyvitamin D) treatment for hospitalized COVID-19 patients showing si
8/28	LateFried et al., Clideath, ↑27.0%, p<Patient Characteristics and Outcomes of 11,Database analysis of 11,721 hospitalized patients, 4,232 on HCQ. Strong evidence for confoundin
8/27	PrEP Ferri at al., Clin cases, $\downarrow 63.0\%$, p COVID-19 and rheumatic autoimmune syste Analysis of 1641 systemic autoimmune disease patients showing csDMARD (HCQ etc.) RR 0.37, p
8/26	LateFiolet et al., Climeta-analysisEffect of hydroxychloroquine with or withoutMeta analysis of late stage studies (and one early treatment study with only 2 deaths), showing H
8/25	Early <i>Ip et al., BMC I</i> death, 154.5%, p Hydroxychloroquine in the treatment of outp Retrospective 1,274 outpatients, 47% reduction in hospitalization with HCQ with propensity matchi
8/25	Late Di Castelnuov death, ↓30.0%, p< Use of hydroxychloroquine in hospitalised C Retrospective 3,451 hospitalized patients, 30% reduction in mortality with HCQ after propensity ad
8/24	Late <i>Catteau et al., I</i> death, ↓32.0%, p< Low-dose Hydroxychloroquine Therapy and Retrospective 8,075 hospitalized patients, 4,542 low-dose HCQ, 3,533 control. 35% lower mortality
8/23	LatePasquini et al.,death, ↓16.4%, pEffectiveness of remdesivir in patients withRetrospective 51 ICU patients under mechanical ventilation, 33 treated with HCQ, showing unadju
8/21	EarlyLy et al., Interndeath, \downarrow 55.6%, pPattern of SARS-CoV-2 infection among depRetrospective analysis of retirement homes, HCQ+AZ >= 3 days mortality OR 0.37, p =0.02. 1690 el
8/21	N/A Lane et al., The safety analysis Risk of hydroxychloroquine alone and in co Retrospective study of RA patients using HCQ vs. sulfasalazine (another DMARD). HCQ treatment
8/21	LateGonzalez et aldeath, ↓26.6%, pThe Prognostic Value of Eosinophil RecoveryRetrospective study focused on eosinophil recovery with 9,644 hospitalized patients in Spain, sho
8/20	Late Dubernet et al., ICU, 187.6%, p=0 A comprehensive strategy for the early treat Retrospective analysis of 36 hospitalized patients showing HCQ/AZ associated with lower ICU ad
8/20	Early <i>Prodromos, C.,</i> safety analysis Hydroxychloroquine is protective to the hear Review concluding that HCQ/AZ does not cause Torsade de Pointes or related deaths, HCQ decre

8/18	Late Pinato et al., C death, \downarrow 59.0% , p< Clinical portrait of the SARS-CoV-2 epidemic Restrospective 890 cancer patients with COVID-19, adjusted mortality HR for HCQ/CQ 0.41, p<0.0
8/15	LatePeters et al., Cldeath, ↑9.0%, p=Outcomes of Persons With COVID-19 in HosRetrospective study of HCQ use in 9 hospitals in the Netherlands, showing no significant differenc
8/14	LateAbd-Elsalam edeath, ↑20.0%, pHydroxychloroquine in the Treatment of COVSmall RCT in Egypt with 97/97 HCQ/control patients, showing 58% more recovery @28days for H
8/13	LateRecommendationRetrospective 176 hospitalized patients (144 HCQ, 32 control) showing no significant differences
8/11	In Sili <i>Tarek et al., European Journal of Drug</i> Pharmacokinetic Basis of the Hydroxychloro <i>In Silico</i> analysis of HCQ treatment showing concluding that HCQ may affect viral clearance if ad
8/11	Early Bakhshaliyev e safety analysis The effect of 5-day course of hydroxychloro Safety study of 109 patients showing 5 days of HCQ+AZ did not lead to clinically significant QT pr
8/11	LateSaleemi et al.,viral- time, ↑21.0Time to negative PCR from symptom onset iRetrospective 65 HCQ+AZ, 20 control patients, showing median time to negative PCR of 23 days f
8/8	LateLopez et al., Int. J. Antimicrob. Agents,Effects of Hydroxychloroquine on Covid-19 iSmall retrospective study of 29 ICU patients comparing those with HCQ plasma concentration wit
8/6	PrEPSalvarani et al.,cases, 16.0%, p=Susceptibility to COVID-19 in Patients TreateComparison of CQ/HCQ users with the general population in a region of Italy, showing no significa
8/6	ReviMcCullough etreviewPathophysiological Basis and Rationale for EReview of pathophysiological principles related to early outpatient treatment and therapeutic appr
8/6	PEP, Watanabe et al meta-analysis Concerns regarding the misinterpretation of Open letter signed by 38 professors and doctors regarding misinterpretation of statistics in HCQ R
8/5	PrEPSinger et al., Acases, \uparrow 9.0%, p=Hydroxychloroquine ineffective for COVID-19Comparison of the percentage of SLE/RA patients on immunosuppressants that were taking HCQ,
8/5	Late <i>Kalligeros et al</i> death, ↑67.0%, p Hydroxychloroquine use in hospitalised patie Small retrospective database analysis of 36 patients receiving HCQ not showing significant differe
8/4	LateKamran et al.,progression, ↓5.0Clearing the fog: Is HCQ effective in reducingStudy of 349 low-risk hospitalized patients with 151 non-consenting or ineligible patients used as

8/3	Late Berenguer et a death, 161.9%, p< Characteristics and predictors of death amo Retrospective 4035 hospitalized patients in Spain showing reduced mortality with HCQ (data is in
8/3	Late Yu et al., Scien progression, 182 Beneficial effects exerted by hydroxychloroq Retrospective 2,882 patients in China, median age 62, 278 receiving HCQ, median 10 days post ho
8/2	Late Davido et al., I int./hosp., 155.0 Impact of medical care including anti-infecti Retrospective of 132 hospitalized patients. HCQ+AZ(52)/AZ(28) significantly reduced death/ICU,
8/2	In Vit Sheaff, R., bio in vitro A New Model of SARS-CoV-2 Infection Base In vitro study presenting a new theory on SARS-CoV-2 infection and why HCQ/CQ provides benefit
8/1	Early Bernabeu-Witt death, ↓59.0%, p Effectiveness of a On-Site Medicalization Pr Retrospective 272 nursing home residents showing significantly improved survival after establishi
7/31	<i>Mazzitelli et al., Travel Medicine and I</i> Apparent inefficacy of hydroxychloroquine c Report on HCQ+AZ use in 41 elderly high-risk patients. 29 of 30 patients with treatment >= 5 days
7/29	Late <i>D'Arminio Mon</i> death, \downarrow 34.0%, p Effectiveness of Hydroxychloroquine in COVI HCQ+AZ adjusted death HR 0.44, <i>p</i> =0.009. Propensity scores include baseline COVID-19 disease s
7/28	Late BaŞaran et al., Turk. J. Med. Sci., doi:1 Outcome of Non-Critical COVID-19 Patients Observational study of 174 hospitalized patients in Turkey, median age 45.4, 23 treated with HCQ,
7/26	PEP <i>Mitjà et al., NE</i> death, ↓51.7%, p A Cluster-Randomized Trial of Hydroxychlor Death rate reduced from 0.6% to 0.4%, RR 0.68, not statistically significant due to low incidence (8
7/24	PrEP <i>Khurana et al.,</i> cases, 151.0%, p Prevalence and clinical correlates of COVID Study of hospital health care workers showing HCQ prophylaxis reduces COVID-19 significantly, O
7/23	Late Cavalcanti et a death, ↓16.0%, p Hydroxychloroquine with or without Azithro Late stage RCT of 667 hospitalized patients with up to 14 days of symptoms at enrollment and re
7/22	In Vit Ou et al., PLOS in vitro Hydroxychloroquine-mediated inhibition of S In Vitro analysis showing that HCQ efficiently blocks viral entry mediated by cathepsin L, but not b
7/22	In Vit <i>Hoffmann et al in vitro</i> Chloroquine does not inhibit infection of hu The title of this paper does not appear to match the results. Fig. 1b @100uM shows CQ results in
7/22	LateRivera et al., Cdeath, ↑2.4%, p=Utilization of COVID-19 Treatments and CliniRetrospective cancer patients, showing adjusted OR 1.03 [0.62-1.73] for HCQ. The study reports th

7/22	LateKelly et al., Britideath, ↑143.0%,Clinical outcomes and adverse events in patiRetrospective 82 hospitalized patients HCQ/AZ, 52 SOC, not finding statistically significant differe
7/21	Late Bernaola et al., death, ↓17.0%, p< Observational Study of the Efficiency of Trea HCQ HR 0.83 [0.77-0.89] based on propensity score matched retrospective analysis of 1,645 hospi
7/20	PrEP Desbois et al., cases, \downarrow 16.9%, p Prevalence and clinical features of COVID-19 Retrospective 199 sarcoidosis patients showing non-statistically significant HCQ RR 0.83, p=1.0.
7/20	Early Risch , H., Ame meta-analysis Response to: "Early Outpatient Treatment of Updated meta analysis including 7 new studies of high-risk outpatients, for a total of 12 studies, al
7/18	PEPWatanabe, M.,meta-analysisEfficacy of Hydroxychloroquine as ProphylaxSecondary analysis of Boulware et al.'s PEP trial and treatment delay-response data, confirming th
7/19	Late McGrail et al., death , ↑70.0% , p COVID-19 Case Series at UnityPoint Health S HCQ+AZ early in the epidemic had a fairly good success rate with few complications, 86% of HCQ
7/17	Late Lyngbakken et death, 13.7%, p= A pragmatic randomized controlled trial repo Small RCT of nasopharyngeal viral load not showing significant differences. The rate of reduction
7/16	Early Hong et al., Inf viral+, 164.9%, p= Early Hydroxychloroquine Administration for HCQ 1-4 days from diagnosis was the only protective factor against prolonged viral shedding foun
7/16	Early <i>Skipper et al.,</i> hosp./death, ↓36 Hydroxychloroquine in Nonhospitalized Adul ~70 to 140 hour (inc. shipping) delayed outpatient treatment with HCQ showing lower hospitalizati
7/16	Early <i>Mitjà et al., Cli</i> hosp., 16.0%, p= Hydroxychloroquine for Early Treatment of A This paper has conflicting values, table S2 shows 12 control hospitalizations, while table 2 shows
7/15	Late Gupta et al., JA death, ↑6.0%, p= Factors Associated With Death in Critically III Analysis of 2215 intensive care unit patients showing no significant differences with this very late
7/15	N/A <i>Kavanagh et al</i> dosing study Inhaled hydroxychloroquine to improve effic Proposal to use an inhaled formulation of HCQ which has passed safety studies in clinical trials fo
7/14	Late <i>Trullàs et al., R</i> death, ↓35.6%, p High in-hospital mortality due to COVID-19 in Retrospective 100 hospitalized patients in Spain showing lower mortality with HCQ+AZ.
7/14	Early Chowdhury et al., Eurasian Journal of A Randomized Trial of Ivermectin-Doxycyclin

	Small 116 patient RCT comparing ivermectin+doxycycline and HCQ+AZ, not showing a significant
7/11	Late Lecronier et al death, 142.0%, p Comparison of hydroxychloroquine, lopinavir Retrospective 80 ICU patients, 22 SOC, 20 lopinavir/ritonavir, 38 HCQ. 28 day mortality 24% (HCQ)
7/10	Late Cravedi et al., death , \uparrow 53.0% , p COVID-19 and kidney transplantation: Result Analysis of 144 hospitalized kidney transplant patients showing HCQ mortality HR 1.53, <i>p</i> = 0.17
7/10	LateChen et al., PLviral+, ↓24.0%, p=A Multicenter, randomized, open-label, contr2 very small studies with hospitalized patients in Taiwan. RCT with 21 treatment and 12 SOC patie
7/9	Late <i>Rivera-Izquierd</i> death, ↓19.0%, p Agentes terapéuticos utilizados en 238 paci Retrospective 238 hospitalized patients in Spain showing lower mortality with HCQ, adjusted haza
7/9	Early, Raoult et al., Pr meta-analysis Hydroxychloroquine and Azithromycin as a T Updated meta analysis showing significant reductions in mortality and viral shedding. Mortality O
7/8	N/AMarzolini et aldosing studyEffect of Systemic Inflammatory Response tStudy of Lopinivar and HCQ plasma concentrations and CRP levels in late stage (treatment initiati
7/8	N/ALi et al., Cell DereviewIs hydroxychloroquine beneficial for COVID-1Review of the anti-inflammatory, antiviral, and protective vascular effects of CQ and HCQ, noting th
7/7	ReviGoldstein, L., PreviewHydroxychloroquine-based COVID-19 Treat85% of globally surveyed physicians recognized HCQ as at least partially effective in treating COVI
7/7	Late An et al., medR viral+, J3.0%, p=0 Treatment Response to Hydroxychloroquine Retrospective of hospitalized patients with 31 HCQ patients and 195 standard treatment patients,
7/3	PrEP Zhong et al., L cases, J91.0%, p COVID-19 in patients with rheumatic disease Rheumatic disease patients on HCQ had a lower risk of COVID-19 than those on other disease-mo
7/1	Late Arshad et al., I death, ↓51.3%, p Treatment with Hydroxychloroquine, Azithro HCQ decreases mortality from 26.4% to 13.5% (HCQ) or 20.1% (HCQ+AZ). Propensity matched HC
7/1	N/A Samuel et al., safety analysis Incidence of arrhythmias and electrocardiog In pediatric patients with PCR positive active COVID-19 infection, significant arrhythmias are infreq
6/30	Late <i>Martinez-Lope</i> death, ↓33.0%, p Multiple Myeloma and SARS-CoV-2 Infection Retrospective 167 multiple myeloma patients in Spain.
6/30	

	Late <i>Mikami et al., J</i> death, ↓47.0%, p< Risk Factors for Mortality in Patients with C HCQ decreases mortality, HR 0.53 (CI 0.41–0.67). IPTW adjustment does not significantly change
6/30	Late <i>Komissarov et</i> viral load, ↑25.0% Hydroxychloroquine has no effect on SARS Small late stage (7-10 days post symptoms) study of nasal swab RNA with 12 control and 33 pati
6/29	Late Sosa-García et death, $\uparrow 10.5\%$, p Experience in the management of severe CO Small retrospective study of 56 ICU patients in Mexico showing HCQ RR 1.1, $p = 1.0$.
6/29	PrEP <i>Ferreira</i> et al., cases, 147.1%, p Chronic treatment with hydroxychloroquine Chronic treatment with HCQ provides protection against COVID, odds ratio 0.51 (0.37-0.70). The a
6/29	N/A <i>Mfeukeu-Kuat</i> safety analysis Electrocardiographic safety of daily Hydroxy No life-threatening modifications of the QT interval was observed in non-severe COVID-19 patients
6/25	PrEP Gendebien et a cases, 13.9%, p= Systematic analysis of COVID-19 infection a Small study of 152 SLE patients taking HCQ with a phone survey for COVID-19 suggestive sympto
6/25	Early Lagier et al., Tr death, ↓59.0%, p Outcomes of 3,737 COVID-19 patients treate Early treatment leads to significantly better clinical outcome and faster viral load reduction. Match
6/23	Late Bousquet et al death, ↓42.8%, p ADL-dependency, D-Dimers, LDH and absenc Observational prospective 108 hospitalized patients 65 and older, showing HCQ mortality OR 0.49,
6/22	Safety Isaksen et al., safety analysis Chloroquine, but not hydroxychlorquine, prol Safety analysis in patients without COVID-19, finding a small increase in QTc associated with use
6/22	Late Fontana et al., death, \downarrow 50.0%, p SARS-CoV-2 infection in dialysis patients in n Very small observational study of 15 dialysis patients showing HCQ mortality RR 0.50, $p = 0.53$.
6/22	Early Chen et al., me viral- time , 172.0 Efficacy and safety of chloroquine or hydrox Significantly faster clinical recovery and shorter time to RNA negative (from 7.0 days to 2.0 days (
6/21	Late <i>Faíco-Filho et</i> viral rate, ↓80.8%, No benefit of hydroxychloroquine on SARS-C Viral load comparison for 34 HCQ and 32 control patients hospitalized with moderate COVID-19. A
6/19	PrEPSMSH SawainewsHCQ beneficial as preventive drug: SMS doctPrEP with 4,300 very high risk healthcare workers in a hospital with up to 500+ COVID patients at a
6/19	LateNIH, study notnewsNIH halts clinical trial of hydroxychloroquineNIH halts late stage trial reporting no harm and no benefit. 470 patients.

6/19	Late Sbidian et al., death, ↑5.0%, p= Hydroxychloroquine with or without azithro Retrospective of 4,642 hospitalized patients in France showing significantly faster discharge with
6/19	N/A <i>Kaptein et al.,</i> animal study Favipiravir at high doses has potent antiviral Animal study with Syrian hamsters, showing treatment of SARS-CoV-2-infected hamsters with favi
6/18	LatePaccoud et al.,death, 11.0%, pCompassionate use of hydroxychloroquine iRetrospective of 89 hospitalized patients, survival HR 0.89 [0.23-3.47], not statistically significant
6/17	Early Capucci et al., J. Cardiovasc. Med. 21, Low hospitalization rate without severe arrhy Prospective analysis of early treatment of 350 patients in Italy (without waiting for PCR results), sh
6/17	LateXue et al., J. Med. Virology, June 17, 2Hydroxychloroquine treatment in COVID-19:30 hospitalized patients. Early use of HCQ is more effective, 43% reduction in progression from m
6/17	Late Luo et al., Ann death, $\uparrow 2.2\%$, p= COVID-19 in patients with lung cancer Analysis of hospitalized lung cancer patients with 35 of 48 taking HCQ, mortality OR 1.03, $p = 0.99$.
6/16	Late <i>Kim et al., Korean J Intern Med, doi:10</i> Lopinavir-ritonavir versus hydroxychloroquin Small retrospective study of hospitalized patients with 31 lopinavir-ritonavir and 34 HCQ patients,
6/16	PrEPWHIP COVID-1newsHenry Ford Health System still moving forwaOngoing WHIP COVID-19 HCQ PrEP study reports analyzing their data and seeing a significantly i
6/16	PrEP <i>Huang et al., A</i> hosp., ↓80.0%, p< Clinical characteristics of 17 patients with C Analysis of 1255 COVID-19 patients in Wuhan Tongji Hospital finding 0.61% with systemic autoim
6/12	TheoScherrmann, AtheoryIntracellular ABCB1 as a Possible MechanisTheory paper, not included in the study count or percentages. Proposes a new mechanism suppor
6/12	LateGiacomelli et al., Journal of Medical ViEarly administration of lopinavir/ritonavir pluLate stage study of hospitalized patients comparing treatment starting within 5 days versus later
6/10	LateWang et al., mdeath, \downarrow 5.8%, p=Comorbidity and Sociodemographic determiDatabase analysis of 7,592 patients in NYC, showing adjusted HCQ mortality odds ratio OR 0.96, p
6/10	Early Otea et al., medRxiv, doi:10.1101/2020 A short therapeutic regimen based on hydro 80 moderate cases, HCQ+AZ appears to reduce serious complications and death. Moderate treate
6/9	Early Pirnay et al., Hosp. Pharm. and Clinici Beneficial effect of Hydroxychloroquine-Azit 68 very high risk nursing home residents, median age 86, HCQ+AZ early treatment within 2.5 days

6/9	PrEPBhattacharyacases, ↓80.7%, pPre exposure Hydroxychloroquine use is assHCQ reduced cases from 38% to 7%. 106 people. No serious adverse effects.
6/6	ReviRoussel et al.,reviewInfluence of conflicts of interest on public poShows a correlation (Spearman test, $p = 0.017$) between the amount received from Gilead Science
6/6	Early,Million et al., Nmeta-analysisClinical Efficacy of Chloroquine derivatives in[H]CQ effective and reduces mortality by a factor 3. Meta analysis of 20 studies.
6/5	Late RECOVERY Col death, ↑9.0%, p= Effect of Hydroxychloroquine in Hospitalized RECOVERY trial finds no significant benefit for very late stage very sick patients. Results may be d
6/3	PEPBoulware et alcases, 17.0%, pA Randomized Trial of Hydroxychloroquine aCOVID-19 cases are reduced by [49%, 29%, 16%] respectively when taken within ~[70, 94, 118] hou
6/1	N/AAl-Kofahi et al.,dosing studyFinding the Dose for Hydroxychloroquine ProAnalysis of HCQ dosing regimens, recommending: PrEP: 800mg loading dose followed by 400mg
5/31	Early Guérin et al., A death, \downarrow 61.4%, p Azithromycin and Hydroxychloroquine Accel Mean clinical recovery time reduced from 26 days (SOC) to 9 days, p<0.0001 (HCQ+AZ) or 13 days
5/28	LateChamieh et al., medRxiv 2020.05.28.2Viral Dynamics Matter in COVID-19 PneumoHCQ+AZ potentially explains 94.7% success in treating a fairly complex cohort.
5/28	PrEPChatterjee et acases, ↓66.8%, pHealthcare workers & SARS-CoV-2 infection i4+ doses of HCQ associated with a significant decline in the odds of getting infected, dose-respon
5/28	LateHuang et al., Nviral- time, ↓67.0Preliminary evidence from a multicenter pro197 CQ patients, 176 control. Mean time to undetectable viral RNA and duration of fever significan
5/27	Late Goldman et al., death, 122.3%, p Remdesivir for 5 or 10 Days in Patients with Study focused on remdesivir but with results for HCQ in the supplementary appendix, showing 9%
5/28	Late <i>Kuderer et al.,</i> death, ↑134.2%, Clinical impact of COVID-19 on patients with Retrospective 928 cancer patients, showing HCQ OR 1.06 [0.51-2.20]. HCQ+AZ OR 2.93 [1.79-4.79]
5/28	PrEP Gianfrancesco hosp., ↓3.3%, p=0 Characteristics associated with hospitalisati Analysis of rheumatic disease patients showing no significant association between antimalarial th
5/27	EarlyRisch, Americameta-analysisEarly Outpatient Treatment of Symptomatic,Five studies, including two controlled clinical trials, have demonstrated significant outpatient treat

5/25	LateIp et al., PLoSdeath, ↓1.0%, p=Hydroxychloroquine and Tocilizumab TherapRetrospective study of late stage use on 2,512 hospitalized patients showing no significant differe	
5/24	LateHraiech et al.,death, ↓64.7%, pLack of viral clearance by the combination ofRetrospective 45 ICU patients, 17 treated with HCQ+AZ, showing no significant difference in viral c	
5/22	PEP,ICMR, Indian CadvisoryRevised advisory on the use of HydroxychlorHealthcare workers on HCQ prophylaxis less likely to get COVID. Significant dose-response relatio	
5/22	LateMehra et al., TretractedHydroxychloroquine or chloroquine with or wIncorrect at first read (implausible death, ventilation, and population numbers). This paper was retr	
5/19	LateSingh et al., mdeath, ↓5.0%, p=Outcomes of Hydroxychloroquine TreatmentEHR analysis of 3,372 hospitalized COVID-19 patients not showing a significant difference for mor	
5/18	LateKim et al., medhosp. time, 151.0Treatment Response to Hydroxychloroquine,Retrospective of 97 moderate cases. Time to viral clearance significantly shorter for HCQ+antibiot	
5/18	Early Ahmad et al., doi:10.1101/2020.05.18 Doxycycline and Hydroxychloroquine as Trea 54 patients in long term care facilities. 6% death with HCQ+AZ compared to 22% using a naive indi	
5/16	PrEPMacias et al.,hosp., 125.5%, p=Similar incidence of Coronavirus Disease 20Very small retrospective study of rheumatic disease patients, sample size is too small for statistic	
5/15	Late Yu et al., Scien death, $\downarrow 60.5\%$, p Low Dose of Hydroxychloroquine Reduces F Retrospective, 550 critically ill patients. 19% fatality for HCQ versus 47% for non-HCQ, RR 0.395, p	
5/14	LateMahévas et al.,death, ↑20.0%, pClinical efficacy of hydroxychloroquine in patObservational study of 181 patients with advanced disease requiring oxygen showing no benefit f	
5/13	LateOkour et al., Journal of PharmacokinetHydroxychloroquine and azithromycin as potOdds of PCR-positive decrease by 53% for each unit increase in HCQ log-concentration. Similarly, t	
5/12	PrEP Cassione et al cases, ↑49.6%, p COVID-19 infection in a northern-Italian coho Survey of 165 SLE patients, 127 on HCQ. 8 patients with suspected COVID-19 and 4 confirmed ca	
5/11	Late Shabrawishi et viral+, 14.7%, p= Negative nasopharyngeal SARS-CoV-2 PCR Retrospective 93 hospitalized patients in Saudi Arabia showing a non-statistically significant 15% r	
5/11	LateRosenberg etdeath, ↑35.0%, pAssociation of Treatment With HydroxychlorRestrospective observational late stage study showing no significant differences but calling for cli	

5/10		Alberici et al., 94 hemodialysis C	death, ↓42.9%, p OVID-19 positive patier	A report from the Brescia Renal COVID Task hts. Reduction in death seen with HCQ but <i>p</i> =
5/8		Grassin-Delyle lung parenchymal e	<i>ex vivo</i> explants, CQ concentra	Chloroquine Inhibits the Release of Inflamm tion clinically achievable in the lung (100 μ M)
5/8			ed. Microbiol., Sep ddition of Zinc to HCQ+	Zinc sulfate in combination with a zinc ionop AZ reduces mortality / transfer to hospice, IC
5/7		Konig et al., An 80 SLE patients di	hosp., ↓ 3.0%, p=0 agnosed with COVID-19	Baseline use of hydroxychloroquine in syste 9, showing the frequency of hospitalisation di
5/7		Derendorf, H., I pharmacokinetic pi	theory roperties of HCQ+AZ as	Excessive lysosomal ion-trapping of hydroxy s a potential underlying mechanism of the ob
5/7		G eleris et al., N ears to be a major e	int./death, <mark>↑4.0%,</mark> error in this paper. Befor	Observational Study of Hydroxychloroquine i re propensity matching, 38 control patients ha
5/7		Sermo (News) by 55% of physiciar	news ns worldwide for COVID	Sermo reports: COVID-19 treatment trends o D. Survey of 6,150 physicians.
5/6		Maisonnasse udy which reports r	-	Hydroxychloroquine use against SARS-CoV Q+AZ. However, there are several signs of effe
5/5		<i>Membrillo de</i> ts hospitalised with	death, ↓55.1%, p COVID-19, HCQ increa	Early Hydroxychloroquine Is Associated with sed survival 1.4 - 1.8 times when patients ad
5/5			<i>Med Infect Dis., 20</i> HCQ+AZ safe and resul	Early Treatment of COVID-19 Patients With ts in a low fatality rate.
5/5		Gendelman et study of rheumatic	cases, ↓8.1%, p= disease/autoimmune	Continuous Hydroxychloroquine or Colchicin disorder patients showing no significant diffe
5/5		Mitchell et al., COVID-19 amongs	death, ↓99.0%, p< at 2.4B people shows a	Markedly Lower Rates of Coronavirus Infecti wide counterintuitive disparity between well
5/4		Huh et al., med analysis of many dr	cases, ↑47.7%, p ugs and COVID-19 case	Association of previous medications with th es, with 23 cases taking HCQ, and 251 control
5/2	Late	Mallat et al., M	viral- time, <mark>↑203</mark>	Hydroxychloroquine is associated with slow

	Very small retrospective analysis of 34 patients finding slower binary PCR viral clearance with HC
5/1	N/AMercuro et al.,safety analysisRisk of QT Interval Prolongation AssociatedStudy of 90 hospitalized patients given HCQ, 53 also receiving AZ, 53% hypertension, 29% diabete
5/1	N/A <i>Bessière et al.,</i> safety analysis Assessment of QT Intervals in a Case Series Study of 40 very serious condition ICU patients, 75% required invasive mechanical ventilation, 63%
5/2	LateSeydi (News) (newsCoronavirus: a study in Senegal confirms thePreliminary results of Senegal trial with 181 patients showing faster recovery with HCQ, and even f
4/30	Early <i>Meo et al., Eur. Rev. Med. Pharmacol.</i> Efficacy of chloroquine and hydroxychloroqu Analysis of COVID-19 and malaria, finding that COVID-19 is highly pandemic in countries where m
4/27	Late Sánchez-Álvar death, ↓45.9%, p Status of SARS-CoV-2 infection in patients o Analysis of 868 patients on renal replacement therapy. Statistically significant reduction in mortalit
4/29	N/ASaleh et al., Cirsafety analysisThe Effect of Chloroquine, Hydroxychloroqui201 hospitalized patients. No serious side effects of HCQ. No instances of Torsade de pointes, or
4/27	N/AKlimke et al.,dosing studyHydroxychloroquine as an aerosol might maProposal to use HCQ as an aerosol in order to reach sufficient therapeutic levels at the alveolar epi
4/26	Late Auld et al., Criti death, ↑2.8%, p= ICU and ventilator mortality among critically Retrospective 217 critically ill patients, 114 receiving HCQ, showing no significant difference in mo
4/25	In Vit Andreani et al., in vitro In vitro In vitro testing of combined hydroxychloroqu HCQ and AZ has a synergistic effect <i>in vitro</i> on SARS-CoV-2 at concentrations compatible with tha
4/24	Early Ashraf et al., m death, ↓67.5%, p COVID-19 in Iran, a comprehensive investiga Small limited trial with 100 patients concluding that HCQ improved clinical outcome, OR 0.016 [0.0
4/21	Late <i>Izoulet M., SSR</i> death, ↓85.0%, p< Countries which Primarily Use Antimalarial D Compares the dynamics of daily deaths in the 10 days following the 3rd death in countries using a
4/21	Late <i>Magagnoli et a</i> death, ↓11.0%, p Outcomes of hydroxychloroquine usage in U Retrospective 807 hospitalized patients, no statistically significant reduction in mortality or the ne
4/17	PEP Lee at al., Int. J. Antimicrob. Agents, 2 Can Post-Exposure Prophylaxis for COVID-1 Post exposure prophylaxis of 211 high-risk people after major exposure event in a long term care
4/16	Late Borba et al., JAMA Network Open, doi: Chloroquine diphosphate in two different do

	Comparison of typical CQ dosage with high dosage CQ (600mg CQ twice daily for 10 days), showi
4/15	Early, <i>Esper et al., Pr</i> hosp., ↓64.0%, p= Empirical treatment with hydroxychloroquine 636 patients. HCQ+AZ reduced hospitalization 79% when used within 7 days (65% overall). Non-ra
4/15	TheoBrufsky, A., JtheoryHyperglycemia, hydroxychloroquine, and theTheory on the effectiveness of HCQ. HCQ has been shown to block the polarization of macrophag
4/14	Late Tang et al., BM viral+ , ↓ 21.4% , p= Hydroxychloroquine in patients with COVID 150 patients very late stage RCT showing no significant difference. Treatment very late, average 1
4/13	LateGao et al., BiosreviewUpdate on Use of Chloroquine/HydroxychlorIncreasing evidence from completed clinical studies shows CQ and HCQ effective (HCQ more effe
4/12	Late Barbosa et al., death, ↑147.0%, Clinical outcomes of hydroxychloroquine in Small retrospective study with 63 patients (32 treated with HCQ), showing no effectiveness, howe
4/11	Early <i>Gautret et al., Travel Medicine and Infe</i> Clinical and microbiological effect of a comb Pilot study suggesting improvement with HCQ+AZ and recommending further study. 80 patients
4/10	LateLover, medRxivmeta-analysisQuantifying treatment effects of hydroxychloSecondary analysis of Gautret et al. showing "modest to no impact of HCQ treatment, with more si
4/3	TheoFantini et al., IntheoryStructural and molecular modelling studies rIn-silico analysis confirming the antiviral properties of CQ, showing a new mechanism of action of
4/1	Early Huang et al., J no recov., ↓91.7% Treating COVID-19 with Chloroquine 22 patients. All CQ patients discharged by day 14 versus 50% of Lopinavir/Rotinavir patients. Sym
3/31	LateChen et al., mepneumonia, ↓57Efficacy of hydroxychloroquine in patients wi62 patients. RCT showing significantly faster recovery with HCQ. 13% progressed to severe cases
3/31	In Vit <i>Clementi et al., in vitro</i> Combined Prophylactic and Therapeutic Use <i>In vitro</i> study, not included in the study count or percentages, showing greater inhibition for combi
3/28	LateMolina et al., Médecine et Maladies InfNo evidence of rapid antiviral clearance or cliReport on 11 patients treated with HCQ with no control group. Authors suggest there is no eviden
3/26	LateZhong Nanshaviral+, ↓80.0%, p<
3/24	

	Theo	<i>Pagliano</i> et al.,	theory	Is Hydroxychloroquine a Possible Post-Expo
	CQ and H	HCQ inhibit replicatio	n at early stages of infe	ection, no similar effect reported for other drug
3/23	Theo	Hu et al., Natur	theory	Insights from nanomedicine into chloroquin
	CQ is kno	own in nanomedicine	e research for the invest	tigation of nanoparticle uptake in cells, and m
3/21	PrEP	ICMR, Indian C	advisory	Advisory on the use of hydroxy-chloroquine
	Recomm	hends HCQ for proph	ylaxis in asymptomatic	healthcare workers as found effective in-vitro
3/20	Late	Hu et al., Shan	news	Shanghai Experience of COVID-19 Managem
	Clinical s	tudies of HCQ with 1	184 cases and 21 hospi	tals show HCQ is effective.
3/18	In Vit HCQ effe			Hydroxychloroquine, a less toxic derivative o tion to direct antiviral activity, HCQ is a safe an
3/17	Early HCQ was	<i>Gautret</i> et al., l s significantly associ		Hydroxychloroquine and azithromycin as a tr imination of viral load, which was enhanced w
3/17	N/A	<i>Sahraei</i> et al., l	review	Aminoquinolines against coronavirus diseas
	Discussi	on of mechanisms o	f action, CQ vs. HCQ, ea	arly studies, safety.
3/13	N/A	Todaro and Ri	review	An Effective Treatment for Coronavirus (COV
	Discussi	on of existing resear	ch, treatment guidelines	s, and mechanisms of action for CQ and HCQ,
3/12	Theo	Devaux et al., I	theory	New insights on the antiviral effects of chlor
	Discusse	es mechanisms of Co	Q interference with the s	SARS-CoV-2 replication cycle.
3/10	N/A	<i>Cortegiani</i> et a	meta-analysis	A Systematic Review on the Efficacy and Saf
	Review c	of six articles and 23	ongoing clinical trials ir	China recommending research and clinical u
3/9	In Vit	Yao et al., Clin	<i>in vitro</i>	In Vitro Antiviral Activity and Projection of Op
	HCQ is n	nore potent than CQ	<i>in vitro</i> for inhibiting SA	RS-CoV-2. Simulates HCQ concentration in lu
3/6	Late	<i>Chen et al., J</i>	progression, ↓29	A pilot study of hydroxychloroquine in treatm
	30 mode	rate hospitalized cas	ses, all recovered. Time	to RNA negative comparable. Less frequent r
3/4	Late	Colson et al., I	review	Chloroquine and Hydroxychloroquine as Avai
	Recomm	nending CQ and HCQ	for COVID-19 based or	a 20 clinical studies in China and a strong ratio
2/20	Late Early tria	-	. Tuberc. Respir. Di results in shorter hospi	Expert Consensus on Chloroquine Phosphat tal stays and improved patient outcomes.

2/19	LateGao et al., BioScience Trends, 2020, dBreakthrough: Chloroquine phosphate has sResults from 15 clinical trials in China showing CQ is effective.
2/17	LateSun, Y., deputynewsAntimalarial drug confirmed effective on COHCQ under clinical trials in >10 hospitals in China and has shown fairly good efficacy.
2/11	Late Xia et al., ChiC viral+, ↓37.5%, p= Efficacy of Chloroquine and Lopinavir/ Riton Early results from a very small trial, reported within the application for a later trial. Very minimal de
2/4	In Vit Wang et al., Ce in vitro Remdesivir and chloroquine effectively inhibi In vitro study, not included in the study count or percentages. Remdesivir and CQ potently blocked
2017	N/AChhonker et aldosing studySimultaneous quantitation of hydroxychloroPresents a method for quantification of HCQ in mouse blood and tissues. They show a lung conce
2014	AnimBrowning, D., Panimal studyPharmacology of Chloroquine and HydroxycReview of the pharmacology of CQ and HCQ. Some notable points: - HCQ and CQ are equipotent b
2014	In Vit <i>de Wilde et al., in vitro</i> Screening of an FDA-Approved Compound Li CQ inhibits SARS-CoV, MERS-CoV, and HCoV-229E-GFP replication in the low-micromolar range.
2012	Anim Yan et al., Cell animal study Anti-malaria drug chloroquine is highly effect CQ, a known autophagy inhibitor that is in clinical use, can efficiently ameliorate acute lung injury a
2009	AnimKeyaerts et al.,animal studyAntiviral Activity of Chloroquine against HumCQ inhibits HCoV-OC43 replication in HRT-18 cells. A lethal HCoV-OC43 infection in newborn C57B
2008	In Vit Kono et al., Ant in vitro Inhibition of human coronavirus 229E infecti CQ significantly decreased viral replication of HCoV-229E at concentrations lower than in clinical u
2006	In Vit Savarino et al., in vitro New insights into the antiviral effects of chlo Update to 2003 paper, not included in the study count or percentages. Hypothesis of CQ inhibiting
2005	In Vit Vincent et al., in vitro Chloroquine is a potent inhibitor of SARS cor In vitro study, SARS-CoV-1, not included in the study count or percentages. CQ has strong antiviral
2004	In Vit <i>Keyaerts et al., in vitro</i> In vitro inhibition of severe acute respiratory <i>In vitro</i> study, SARS-CoV-1, not included in the study count or percentages. IC50 of CQ for antiviral
2003	TheoSavarino et al.,theoryEffects of chloroquine on viral infections: anNot included in the study count or percentages. Discussion/review noting that CQ exerts antiviral

1918	N/A <i>Burrows, E., Medical Record,</i> 97:6, 235, A confirmatory report upon the abortive acti Quinine was found to be effective for the Spanish Flu in 1918.
1901	N/A Yeo, B., 1901 (Peer Reviewed) (not incl A manual of medical treatment or clinical th Quinine is refered to as "the remedy that is most deserving of confidence in the treatment of influe
1894	AnimMossé, Lancet,animal studyPathogenesis and Treatment of InfluenzaLancet study showing quinine protected rabbits from influenza and recommending use for prophy
1890	N/ALe Grelot (NewnewsQuinine use for the Russian influenze pandeQuinine and antipyrine, a bitherapy for defying death during the Russian influenza pandemic of 18
1889	N/AEdwin Wiley GrnewsLaxative Bromo QuinineQuinine has been used for respiratory infections since 1889. Not included in the study count or per

For search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), PRISMA answers, and statistical methods see hcqmeta.com. In Vitro, Ex Vivo, Meta, Theory, Safety, Review, News, and Retracted items are not included in the study count. There is a total of 388 items. Studies with preprints and journal versions are listed under the earlier preprint date.